Katharine M. Stohlman
Keine laufenden Positionen mehr
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Heidi Fields | F | 69 | 24 Jahre | |
| Dominique Grau | M | 64 | 25 Jahre | |
| Rodney Gonsalves | M | 58 | 25 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| William Sullivan | M | 74 | 16 Jahre | |
| Didier Hirsch | M | 72 | 19 Jahre | |
| Edward Barnholt | M | 81 | 6 Jahre | |
| Todd F. Davenport | M | 73 |
Viacor, Inc.
 Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 Jahre |
| James Cullen | M | 81 | - | |
| Richard T. Spencer | M | 87 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 Jahre |
| Richard A. Burdsall | M | - | - | |
| Neil Dougherty | M | 55 | - | |
| David M. Lawrence | M | 83 | 15 Jahre | |
| Hilliard Terry | M | 54 | 13 Jahre | |
| Robert John Herbold | M | 81 | - | |
| Christopher D. Hutchins | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 25 Jahre |
| D. Craig Nordlund | M | 74 | 10 Jahre | |
| Kristin Giffin | F | - | - | |
| Gregory Lambrecht | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | - |
| Adrian Dillon | M | 70 | 9 Jahre | |
| A. Barry Rand | M | 79 | 15 Jahre | |
| William T. Hayes | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 Jahre |
| Alicia Rodriguez | F | - | - | |
| Frank Ostojic | M | - | - | |
| Jessica Denecour | F | 62 | 6 Jahre | |
| Herb F. Ostenberg | M | 74 | 10 Jahre | |
| Barney E. Saunders | M | 61 | 4 Jahre | |
| Anya Yudin-Baehrle | F | - | 10 Jahre | |
| Stanley B. Kyi | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 Jahre |
| James P. Yano | M | 57 | 4 Jahre | |
| Frederick A. Kish | M | - | 2 Jahre | |
| Tze-Siong Chong | M | - | 8 Jahre | |
| Soon Chai Gooi | M | 63 | 28 Jahre | |
| Hong Kiat Leong | M | - | 5 Jahre | |
| Jerry Grinstein | M | - | 3 Jahre | |
| Sam Tan | M | - | - | |
| Bill James Peck | M | 64 | 8 Jahre | |
| John B Smith | M | - | 5 Jahre | |
| Lynne J. Camp | F | 66 | 10 Jahre | |
| Matthew Randall | M | - | 5 Jahre | |
| Mark Wallace | M | 59 | - | |
| Kim Seng Lim | M | 58 | 3 Jahre | |
| Kah Khim Wee | M | 55 | 11 Jahre | |
| Liang Horng Wang | M | - | 2 Jahre | |
| Hajime Tada | M | - | 16 Jahre | |
| Michael T. Wende | M | 66 | 11 Jahre | |
| Catherine Williams | F | 75 | 19 Jahre | |
| Robert Cantrell | M | - | 17 Jahre | |
| Alan W. Marty | M | - | - | |
| Jonathan Mazelsky | M | 63 | 5 Jahre | |
| Yih-Neng Lee | M | 65 | 4 Jahre | |
| Jeffrey A. Miller | M | 68 | - | |
| David Eisenmann | M | - | - | |
| Gregory Matz | M | 64 | 11 Jahre | |
| Guy Séné | M | 68 | - | |
| Shiela Barr Robertson | F | - | - | |
| Alan Grahame | M | 71 | 8 Jahre | |
| Julie Ione Morris | F | - | 7 Jahre | |
| Hans-Joachim Wagner | M | 64 | 8 Jahre | |
| John W. Schoen | M | 68 | 1 Jahre | |
| Paul M. Barics | M | 61 | 5 Jahre | |
| Pascal Rondé | M | 62 | 6 Jahre | |
| Kristen Robinson | F | 61 | 6 Jahre | |
| Jeffrey H. Barnes | M | 62 | 2 Jahre | |
| Patrick Byrne | M | 63 | 8 Jahre | |
| Sharon Holt | F | 59 | 5 Jahre | |
| John C. Boutsikaris | M | 76 | 11 Jahre | |
| David J. Allen | M | 69 | 7 Jahre | |
| Saleem N. Odeh | M | 73 | - | |
| Richard D. Kniss | M | 82 | 2 Jahre | |
| Thomas A. Saponas | M | 74 | 4 Jahre | |
| Christopher van Ingen | M | 77 | 6 Jahre | |
| Dorothy Hayes | F | 73 | 4 Jahre | |
| Alain A. Couder | M | 78 | 2 Jahre | |
| Byron J. Anderson | M | 79 | 5 Jahre | |
| Thomas E. White | M | 67 | - | |
| Dietmar Höller | M | 66 | 6 Jahre | |
| Earl R. Thompson | M | 62 | 5 Jahre | |
| Anthony Salerno | M | 70 | 5 Jahre | |
| William Cohn | M | 64 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 16 Jahre |
| Julian Elliott | M | - | 3 Jahre | |
| Amir Aghdaei | M | 66 | 7 Jahre | |
| A. Marc Gillinov | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 13 Jahre |
| Michael Vargas | M | 64 | 5 Jahre | |
| Jean Nye | F | 71 | 15 Jahre | |
| Aislinn Rice | M | - | 2 Jahre | |
| Martin Scott | M | 68 | 6 Jahre | |
| Darlene Solomon | M | 65 | 24 Jahre | |
| Robert R. Walker | M | 72 | 2 Jahre | |
| John Liddicoat | M | 60 |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 13 Jahre |
| David S. Marks | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 7 Jahre |
| Jacob Bell | M | - | 14 Jahre | |
| Jonathan M. Rourke | M | - |
Viacor, Inc.
Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 Jahre |
| Jagjit S. Sahota | M | - | 2 Jahre | |
| Neal J. Carney | M | 68 | 2 Jahre | |
| Giovanni Barbarossa | M | 62 | 1 Jahre | |
| Haresh P. Patel | M | 62 | - | |
| Rick Lazansky | M | - | 13 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 97 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Katharine M. Stohlman
- Persönliches Netzwerk
